The alliance is based on a simple premise: City of Hope provides a state-of-the-art clinical setting in which to advance genomic breakthroughs made by TGen.
It is a collaboration that plays to the strengths of each organization. City of Hope is a pioneer in the fields of bone marrow transplantation, hematologic malignancies, select solid tumors and diabetes. TGen, meanwhile, is a leader in applying genomic analysis and bioinformatics to cancer drug development.
Together, they are transforming the diagnosis, treatment and prevention of cancer and other life-threatening diseases.
It's all part of the organizations' efforts to augment their expertise in precision medicine, a rapidly evolving field that involves using an individual’s underlying genetic profile to guide clinical decisions, including the diagnosis and treatment of disease.
This alliance provides City of Hope with access to TGen's innovative genomics technologies, helping physicians and researchers move research discoveries into the clinic for the benefit of patients.
What is Precision Medicine?
Dr. Jeffrey Trent and Dr. Muhammad Murtaza of TGen, an affiliate of City of Hope, discuss the significance of liquid biopsies in the diagnoses and management of life-threatening diseases.